Europe — EMA
Omjjara (Momelotinib)
Momelotinib, the active ingredient in Omjjara, is a drug presented as a oral formulation for oral use. It is being investigated for the treatment of myelofibrosis and related blood disorders in adult patients.
Request sourcing
What is Momelotinib?
Momelotinib, the active ingredient in Omjjara, is a drug presented as a oral formulation for oral use. It is being investigated for the treatment of myelofibrosis and related blood disorders in adult patients. GNH USA supplies Omjjara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
GNH USA supplies Omjjara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
What is Momelotinib used for?
Omjjara (momelotinib) is an oral targeted therapy that is being studied in myelofibrosis and related .
- Myelofibrosis: ... .... ... . - Secondary .... .... .... . - .... .... .... .
What are the side effects of Momelotinib?
The ... …
What precautions apply to Momelotinib?
...
